Rotation from subcutaneous infusion to transdermal administration of fentanyl: A validation ofcurrent practice

Erasmus MC0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•Age > 18 years
•Able to understand the written information and able to give informed consent.
•Current treatment with subcutaneous fentanyl and planned to rotate to transdermal
•To ensure steady-state kinetics, patients must have been treated with
•subcutaneous fentanyl for at least 40 hours prior to the rotation and have been
•treated with a stable fentanyl dose at least 20 hours prior to the rotation This way,
•fentanyl pharmacokinetics are at steady-state.

•Patients that use short-acting fentanyl via the oral, (oral mucosal, sublingual),
•intranasal or subcutaneous administration route 12 hours prior to the rotation will
•be excluded as this influences the pharmacokinetic profile of the subcutaneous
•administration. This implicates that patients will be prescribed oral short acting
•oxycodone or morphine 12 hours before rotation as these are mostly used next to
•treatment with transdermal fentanyl.
•Patients that use strong CYP3A4 inhibitors or inducers will be excluded as the
•model did not account for the influence of strong CYP3A4 inhibition or induction on
•fentanyl pharmacokinetics while the effects have been shown in multiple studies
•Patients that are rotated using a dose conversion ratio other than 1:1 will also be

发起方